Suppressor T Cells in Human Diseases by Baecher-Allan, Clare & Hafler, David A.
T
h
e
 
J
o
u
r
n
a
l
 
o
f
 
E
x
p
e
r
i
m
e
n
t
a
l
 
M
e
d
i
c
i
n
e
 
J. Exp. Med. 
 
©
 
 The Rockefeller University Press • 0022-1007/2004/03/273/4 $8.00
Volume 200, Number 3, August 2, 2004 273–276
http://www.jem.org/cgi/doi/10.1084/jem.20040812 
 
Commentary
 
273
 
Suppressor T Cells in Human Diseases
 
Clare Baecher-Allan and David A. Haﬂer
 
Laboratory of Molecular Immunology, Center for Neurologic Diseases, Brigham and Women’s Hospital and Harvard 
Medical School, Boston, MA 02115
 
Although central and peripheral tolerance are important
for the regulation of human immune responses to self- and
microbial antigens, an important role of suppressor CD4
 
 
 
CD25
 
 
 
 T cells is suggested from the recent investigations
of human autoimmune diseases and HIV. These new data
provide increasing evidence that altered function of CD4
 
 
 
CD25
 
 
 
 T cells may be an important factor in a wide range
of human inflammatory and infectious diseases.
A curious finding in our understanding of human autoim-
mune diseases has been the presence of self-reactive T cells
in the circulation of healthy individuals, as measured by in
vitro cloning techniques, without evidence of disease (1).
Although central tolerance clearly exerts a major effect in
selecting the repertoire of T cells recognizing self-antigens,
it is likely that peripheral tolerance is not the sole protector
against autoimmune disease. Moreover, although the field
of immunology discarded suppressor T cells almost two
decades ago, when prevailing views of their mechanism
could not stand the scrutiny of molecular biology, it was
clear to investigators performing experiments in animal
models of autoimmune disease that populations of T cells
existed that could be adoptively transferred to prevent the
onset of clinical disease.
The past decade has seen the discovery of several T cell
populations that appear to have major regulatory effects on
T cells responding to both self-antigens and those derived
from infectious agents. As is frequently the case, these regu-
latory T cell populations were discovered first in experi-
mental animal models and subsequently identified in humans.
They can broadly be divided into T cells that appear to require
antigen-specific, MHC-restricted stimulation, with subse-
quent secretion of cytokines that down-regulate immune
responses—the prototypic Tr1 and Th3 cells, which secrete
IL-10 and TGF-
 
 
 
, respectively (2–5)—or more innate regula-
tory cells that do not appear to require an in vivo “adaptive”
immunization to observe their function—the CD1-restricted
NKT cells with invariant TCRs, “nonclassical” NK T cells
with variant TCRs (6, 7), and the CD4
 
 
 
CD25
 
 
 
 regulatory
T cells (8, 9).
After a decade of investigation in animal models of hu-
man disease, a series of recent articles in the 
 
Journal of Exper-
imental Medicine
 
, including this issue, have placed CD4
 
 
 
CD25
 
 
 
 T cells as regulators of human immune responses
in both autoimmune (10–12) and infectious diseases (13).
The potential role of CD4
 
 
 
CD25
 
 
 
 T cells in human dis-
ease presents a striking example of the essential interaction
between basic investigation in animal models, both in vivo
and in vitro, and clinical investigation of human disease, al-
lowing a greater degree of confidence in the validity of the
in vitro observation in humans.
 
From Mouse Regulatory T Cells to Human.
 
The discov-
ery of CD4
 
 
 
CD25
 
 
 
 T cells was based on a simple in vivo
observation: mouse thymectomy on neonatal day 3 leads to
the development of multiorgan autoimmune disease (14).
Seminal experiments performed by Sakaguchi and coworkers
demonstrated that it was the depletion of CD4
 
 
 
CD25
 
 
 
 cells
that resulted in the onset of systemic autoimmune diseases in
these neonatally thymectomized mice (15, 16), and cotransfer
of these cells with CD4
 
 
 
CD25
 
 
 
 cells prevented the develop-
ment of experimentally induced autoimmune diseases such
as colitis, gastritis, insulin-dependent autoimmune diabetes,
and thyroiditis (17–23). In sum, these investigations demon-
strated that in mice CD4
 
 
 
CD25
 
 
 
 cells can regulate the re-
sponses of autoreactive T cells in vivo. The discovery of the
importance of the transcriptional regulator FoxP3 in mouse
CD4
 
 
 
CD25
 
 
 
 T regulatory cell function (24, 25) and the
previous observations that patients with IPEX (immune dys-
regulation, polyendocrinopathy, enteropathy, and X-linked
inheritance), a severe inflammatory disease similar to that
seen in mice deficient in CD4
 
 
 
CD25
 
 
 
 regulatory cells, have
mutations in 
 
FOXP3
 
 (26), provided a direct correlation be-
tween an autoimmune animal model, mouse regulatory T
cells, and a human autoimmune disease.
 
Defining Human CD4
 
 
 
CD25
 
 
 
 Regulatory T Cells.
 
How-
ever, then how could CD4
 
 
 
CD25
 
 
 
 regulatory T cells be
investigated in humans? The in vitro assay developed by
Shevach and coworkers (27), where the addition of mouse
CD4
 
 
 
CD25
 
 
 
 T cells to CD4
 
 
 
CD25
 
 
 
 T cells resulted in
suppression of proliferation at ratios of up to 
 
 
 
1:10 sup-
pressor to target T cells, provided a convenient assay of T
regulatory function. However, if a human CD4
 
 
 
 T cell
population inhibits the proliferation of other T cells in
vitro and was isolated solely by expression of CD25, is it
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the same CD4
 
 
 
CD25
 
 
 
 regulatory T cell population ob-
served in mice where CD4
 
 
 
CD25
 
 
 
 cells are isolated from
animals kept in germ-free facilities with low levels of en-
dogenous T cell activation? Since CD25 can also be ex-
pressed by activated T cells, how can we know that the
human CD4
 
 
 
CD25
 
 
 
 regulatory T cell populations now
reported by many different groups (9, 28–30) are capable of
suppressing immune responses in vivo? Since there is no
unique cell surface marker expressed by regulatory T cells,
it is difficult to enumerate and analyze these cells.
Heterogeneity of the isolated T regulatory cell popula-
tions may explain the contradictory findings as to the mode
of action of CD4
 
 
 
CD25
 
 
 
 T regulatory cells. Human
CD4
 
 
 
CD25
 
 
 
 regulatory T cells have been varyingly re-
ported to suppress by mechanisms that involve either IL-
10, or TGF-
 
 
 
, or CTLA4, or none of the above (9, 28, 29,
31–34). During our own initial investigations to determine
if suppressive CD4
 
 
 
CD25
 
 
 
 T cells existed in human pe-
ripheral blood, we demonstrated that the separation of
CD4
 
 
 
 T cells into CD25
 
neg
 
, CD25
 
med
 
, and CD25
 
high
 
 sub-
sets by FACS
 
®
 
 sorting resulted in the segregation of an
IL-10–, TGF-
 
 
 
–, and CTLA4-independent but cell con-
tact–dependent suppression only with the CD25
 
high
 
 subset
(9). Moreover, the CD25
 
high
 
 subset was predominantly
CD62L
 
high
 
 (
 
 
 
95%), a hallmark for resting cells that have
not been recently activated. In contrast, the CD25
 
med
 
 pop-
ulation exhibits functional variability in vitro: they can ei-
ther enhance or suppress proliferation in cocultures and
they actually contain the majority of recently activated
CD62L
 
lo/
 
 
 
 CD4
 
 
 
 cells in the circulation. Similar to mouse
CD4
 
 
 
CD25
 
 
 
 cells, these human CD4
 
 
 
CD25
 
high
 
 T cells
are unresponsive to in vitro antigenic stimulation (anergic)
and strongly suppress the proliferation of responder T cells
upon coculture (9).
 
CD4
 
 
 
CD25
 
 
 
 T Regulatory Cells in Human Autoimmune
Disease.
 
The discovery of methods to evaluate the in vitro
function of CD4
 
 
 
CD25
 
 
 
 T cells in humans has allowed the
importance of these regulatory T cells in human immune
responses and disease to be examined. As discussed earlier,
self-antigen–reactive T cells are present in healthy individu-
als and in patients with autoimmune disorders. The finding
that autoreactive T cells found in patients with autoimmune
disease are more easily activated than those from normal
subjects (35, 36) leads to the hypothesis that regulatory T
cells may normally suppress the activation of self-reactive T
cells, and either deficient generation or reduced effector
function of these CD4
 
 
 
CD25
 
high
 
 cells plays a role in the de-
velopment of autoimmunity. Consistent with this hypothe-
sis is the recent work by Danke et al. demonstrating that
deletion of CD4
 
 
 
CD25
 
 
 
 T cells allows marked clonal ex-
pansion of human autoreactive T cells in vitro (37).
Multiple sclerosis (MS) is the most common neurologic
disease of young adults (38). We compared the frequency
and function of CD4
 
 
 
CD25
 
high
 
 T cells derived from
patients with MS with those from healthy control sub-
jects. Although we found no change in the frequency of
CD4
 
 
 
CD25
 
high
 
 cells, there was a marked decrease in their
effector function (10). Using CD4
 
 
 
CD25
 
high
 
 populations
that were 
 
 
 
98% CD62L
 
high
 
, the coculture suppression by
patient-derived CD4
 
 
 
CD25
 
high
 
 cells was 20%, whereas the
suppression by CD4
 
 
 
CD25
 
high
 
 cells isolated from healthy
control subjects was 80%. Differences were also apparent in
single cell cloning experiments, in which the cloning fre-
quency of CD4
 
 
 
CD25
 
high
 
 T cells was substantially reduced
in patients compared with normal controls. As the strength
of signal delivered through the TCR of target T cells is one
factor determining whether regulatory CD4
 
 
 
CD25
 
high
 
 T
cells can suppress the responder T cell proliferation (39),
several different strength stimuli were used to properly ex-
amine the function of CD4
 
 
 
CD25
 
high
 
 T cells in controls
and in patients with MS. A strong signal provided by maxi-
mal concentration of plate-bound anti-CD3 mAb abrogated
suppression in both patient and control cocultures. In con-
trast, using lower concentrations of plate-bound anti-CD3
allowed a defect in the suppressive ability of CD4
 
 
 
CD25
 
high
 
regulatory cells derived from patients with MS to become
apparent. Importantly, comixing experiments demonstrated
that the decrease in T cell regulatory function was due to a
defect in the CD4
 
 
 
CD25
 
high
 
 T cell subset rather than the
possibility that the responder CD4
 
 
 
CD25
 
 
 
 T cells were re-
fractory to suppression because of the presence of activated
autoreactive T cells in the patient samples.
The potential involvement of CD4
 
 
 
CD25
 
high
 
 T cells in
human autoimmune polyglandular syndromes (APS), in
which several organ-specific autoimmune diseases are clus-
tered, has also been investigated recently (11). There are
two variants of APS: type I, which is caused by loss of cen-
tral tolerance, and type II (APS-II), which is of unknown
etiology. As depletion of CD4
 
 
 
CD25
 
  
 
regulatory T cells in
mice causes a syndrome with multiple endocrinopathies re-
sembling APS-II, Kriegel et al. (11) examined whether de-
fects in peripheral CD4
 
 
 
CD25
 
high
 
 T cells would be found
in APS-II. As observed in MS, CD4
 
 
 
CD25
 
high
 
 T cells in
patients with APS-II were found at normal frequency but
were defective in their suppressive capacity. Furthermore, as
in patients with MS the defect was shown not to be due to
responder cell resistance, suggesting that the pathogenesis of
APS-II is related to the function of these regulatory T cells.
Alterations in regulatory CD4
 
 
 
CD25
 
high
 
 T cells have also
been reported in patients with rheumatoid arthritis (40) and
in patients with juvenile idiopathic arthritis (41). These stud-
ies examined CD4
 
 
 
CD25
 
 
 
 cells directly at the sites of in-
flammation and in the peripheral blood, although the poten-
tial involvement of IL-10 or TGF-
 
 
 
 were not examined.
Interestingly, the frequency of CD4
 
 
 
CD25
 
high
 
 T cells was
much greater in the synovial fluid compared with the periph-
eral blood in adult patients with rheumatoid arthritis. Patients
with the juvenile disease also exhibited similar increases in
synovial fluid CD4
 
 
 
CD25
 
high
 
 cells; however the patients
with the more favorable prognostic form of the disease also
exhibited an increased frequency of CD4
 
 
 
CD25
 
high
 
 T cells
in the peripheral blood. When these regulatory T cells were
isolated from the joint and tested in vitro, they demonstrated
suppressive activity. As these studies find differences in the
frequency of CD4
 
 
 
CD25
 
high
 
 regulatory T cells isolated from
the target tissue compared with the peripheral blood, they 
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suggest that regulatory T cells migrate into the joint and are
either inactivated by inflammatory mediators, or alterna-
tively, the enhanced number of regulatory T cells in the syn-
ovium may actually initiate the resolution of the episode of
immune activity. The observation that the form of JIA with
better prognosis correlates with enhanced numbers of pe-
ripheral CD4
 
 
 
CD25
 
high
 
 cells is also of interest since it sug-
gests that peripheral expansion of regulatory T cells may oc-
cur in this subset of patients. However, the major question
remains as to whether regulatory T cells are able to function
in the synovial fluid milieu as rheumatologic disease exists in
the target tissue in the face of an enhanced number of regula-
tory T cells that are highly suppressive in vitro.
A new study by Ehrenstein et al. published in this issue
(12) further suggests that regulatory T cells may be expanded
in vivo in patients with rheumatoid arthritis that respond fa-
vorably to treatment with anti-TNF  therapy. Specifically,
they demonstrate that the CD4 CD25high cells isolated from
the peripheral blood of patients with active rheumatoid ar-
thritis can suppress the responder CD4 T cell proliferative
response but not the secretion of inflammatory cytokine. In
contrast, CD4 CD25high cells isolated from patients after
anti-TNF  therapy suppress both proliferation and cytokine
secretion. These data may underscore the central role for cy-
tokines in maintaining the inflammatory state in vivo. The
authors demonstrated that the ability of bead-isolated CD4 
CD25  T cells to induce a “suppressive phenotype” after
culture with CD4 cells did not occur with regulatory T cells
isolated from patients with active disease but did occur in
cells isolated after anti-TNF  therapy. Moreover, the
suppressive activity was restricted to the CD25high subset
compared with CD4 CD25lo cells. Although this analysis
focused on cells in the blood compared with the syn-
ovium, the correlation between anti-TNF  responders,
CD4 CD25high frequency, and in vitro suppressor activity
suggests that the activity of regulatory T cells in the periph-
eral blood may reflect what is occurring in the affected joints.
A Role for CD4 CD25  T Regulatory Cells in HIV.
Also in this issue, the importance of CD4 CD25high regula-
tory T cells is extended with a report examining a role for
regulatory cells in HIV infection. HIV is associated with
loss of CD4  T cells and progressive CD4  T cell immune
dysfunction, leading to impaired HIV responses early after
infection (13). Kinter et al. hypothesized that the basis for
the decrease in response to HIV relates to defects in
CD25 CD4  regulatory T cells. In fact, they observed that
in the majority of healthy yet HIV-infected individuals,
CD25 CD4high T cells significantly suppressed cellular pro-
liferation and cytokine production by CD4  and CD8  T
cells in response to HIV antigens/peptides in vitro. As in
patients with MS, these in vitro effects were cell contact
dependent and IL-10 and TGF-  independent. Paradoxi-
cally, they also found that patients with strong HIV-specific
CD4 CD25high function in vitro had significantly lower
levels of plasma viremia and higher CD4  to CD8  T cell
ratios than patients without regulatory T cell activity. These
data suggest that suppression of CD4 T cell activation by
regulatory T cells may make HIV replication less favorable,
possibly because these cells suppress the activation of CD4 
T cells and thus make fewer target cells available.
Concluding Remarks. It appears that CD4 CD25high
regulatory cells modulate immune responses to self-anti-
gens and infectious agents in humans. The possibility that
CD4 CD25  regulatory T cells may have expanded in
vivo, one interpretation of the observed increases in regula-
tory T cell frequency in the peripheral blood of patients
with JIA and rheumatoid arthritis, indicates that the design
of therapies that induce CD4 CD25high cell expansion may
be of clinical relevance. The parallel observations relating
CD4 CD25  regulatory cells in animal models of autoim-
munity and human inflammatory diseases indicate that sup-
pressor cells are back to stay as central regulators of immune
responses in human diseases.
We would like to thank Dr. Vijay Kuchroo for helpful discussion
and for critically reading the manuscript.
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